Search Results for: ANTIBODY DRUG CONJUGATES ADC Development
Articles
ANTIBODY DRUG CONJUGATES - ADC Development Using SMARTag(TM) Technology April 1, 2014
Robyn M. Barfield, PhD, and David Rabuka, PhD, say that despite challenges, there has been progress in advancing complex compounds through clinical trials and successfully treating patients, and these bioconjugate compounds include a subset of molecules known as ADCs.
Veranova Devens Site Breaks Ground on ADC Facility Expansion June 20, 2025
Devens, MA, USA — Government officials, industry leaders, and local business representatives gathered yesterday to mark the groundbreaking of Veranova’s...Adcendo ApS Announces First Patient Dosed in Phase 1/2 ADCElerate1 Trial of ADCE-D01 June 10, 2025
Adcendo recently announced the first patient has been dosed in the Phase 1/2 ADCElerate1 clinical trial evaluating ADCE-D01 in patients...OBI Pharma Enters ADC Collaboration With TegMine Therapeutics Utilizing GlycOBI & TegMiner Enabling Technologies June 6, 2025
OBI Pharma, Inc. and TegMine Therapeutics, Inc. have entered into an ADC-related Master Services Agreement (MSA). Under the terms of...SPECIAL FEATURE- Outsourcing Formulation Development & Manufacturing: CDMOs Are Making Their Supply Chains More Resilient & Secure June 4, 2025
Contributor Cindy H. Dubin speaks with many CDMO professionals to get their insights and perspectives on the current state of the industry.
BioNTech & Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop & Co-Commercialize Next-Generation Bispecific Antibody Candidate Broadly for Multiple Solid Tumor Types June 2, 2025
BioNTech SE and Bristol Myers Squibb recently announced they have entered into an agreement for the global co-development and co-commercialization...Avidicure Launches With $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer April 24, 2025
Avidicure recently announced its launch with a $50 million seed financing round, led by EQT Life Sciences with participation from...ADC PAYLOADS - Progress in Development of Camptothecin-Based ADC Therapeutics April 4, 2025
Paul Moore, PhD, Raffaele Colombo, PhD, and Jamie Rich, PhD, say the recent progress in research on novel camptothecin payloads highlights the potential for developing a new generation of ADCs that can overcome some of the limitations of first-generation therapies.
EXECUTIVE INTERVIEW - Lonza: Driving Innovation & Sustainability: CDMO Trends & the Future of ADCs April 3, 2025
Sebastian Stenderup, Executive Director, Head of Commercial EMEA, Lonza, discusses some of the trends CDMOs are currently facing, from the growth of ADCs to the importance of sustainability, and how his company is responding to them.
Axplora Expands Commercial Payload Production Capabilities at Le Mans to Strengthen its Leading Position in ADC Manufacturing March 4, 2025
Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is strengthening its leading position in the...OUTSOURCING PHARMA DEVELOPMENT - Harnessing CDMOs for Innovation & Efficiency February 10, 2025
Rohtash Kumar, PhD, says a strategic partnership with a trusted CDMO can provide many benefits ranging from experts’ insights to state-of-the-art equipment. However, there are several considerations that developers should evaluate prior to engaging with a CDMO to maximize their partnership.